Keynote Speakers
Peter H. Seeberger
Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany
Vaccines, antibody therapies and diagnostics based on synthetic carbohydrates
Stephan Bachmann
F. Hoffmann-La Roche Ltd.,
Basel, Switzerland
Catalytic applications in the scale-up of API processes
Frank Wagner
Charité, Berlin, Germany
Clinical trial design: A paradigm shift in early clinical trials
Invited Speakers
Daniela Angst
Novartis
Discovery of remibrutinib, a covalent BTK inhibitor
Roy Bar-Ziv
Weizmann Institute of Science, Rehovot, Israel
TBD
Martina Benešová
German Cancer Research Center
Molecular Biology of Systemic Radiotherapy
Andrea Brancale
UCT Prague, ČR
Advances in computer-aided drug design
Oliviana Calin-Eller
E. Blum & Co. AG, Zurich, Switzerland
Patents in Medicinal Chemistry/Life Science
Richard Clarkson
Cardiff University, UK
Assessing efficacy of new anticancer treatments at pre-clinical level
Camille Correia
Merck Electronics KGaA, Darmstadt, Germany
Modular continuous automation for laboratories and production
Deborah Fass
Weizmann Institute of Science, Rehovot, Israel
Structures of mucin glycoproteins inspire molecular methods for modulating mucosal functions
Paulina Kaplonek
Moderna, USA
Identifying the correlates of immunity for better vaccine design
Valery Khrizanovsky
Weizmann Institute of Science, Rehovot, Israel
Senescent cells in aging and age-related disease: the good, the bad and the ugly
Jan Konvalinka
IOCB Prague, ČR
Chemical-biology tools in drug development
Sima Lev
Weizmann Institute of Science, Rehovot, Israel
Combination therapy and drug resistance in TNBC
David Margulies
Weizmann Institute of Science, Rehovot, Israel
Artificial Protein Crosstalk, Combinatorial Sensing, and Bacterial Cell Surface Engineering with Molecules that Interact with Distinct Protein Partners
Petra Ménová
UCT Prague, ČR
Drug discovery and development
Johan Neyts
KU Leuven, Belgium
Discovery and development of antiviral drugs
Jitka Palich Fučíková
Sotio Biotech Department of Immunology, 2nd Medical school, Charles University
The immune contexture in cancer prognosis and response to immunotherapy
Christoph Rademacher
University of Vienna
Molecular drug targeting
Pavlína Řezáčová
IOCB Prague, ČR
Structure-assisted design of enzyme inhibitors
Jitka Riedl
Bicycle Therapeutics, Cambridge, UK
Bicycle peptides as precision-guided cancer therapeutics
Menachem Rubinstein
Weizmann Institute of Science, Rehovot, Israel
Directing viral vectors to specific cell types for oncolytic virotherapy and in vivo gene therapy
Gideon Schreiber
Weizmann Institute of Science, Rehovot, Israel
Reversing protonation of weakly basic drugs greatly enhances intracellular diffusion and decreases lysosomal sequestration
Marek Šťastný
Bristol-Myers Squibb
Cancer immunotherapies based on anti-PD1: clinical perspectives and challenges
Kvido Stříšovský
IOCB Prague, ČR
The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling
Michal Tichý
IOCB Prague, ČR
Kinase Inhibitors: From insoluble and promiscuous hit to drug candidate
Igor Ulitsky
Weizmann Institute of Science, Rehovot, Israel
Therapeutic targeting of RNA molecules
Kateřina Vávrová
Faculty of Pharmacy Hradec Kralove, Charles University, ČR
Transdermal drug administration
Milan Vrábel
IOCB Prague, ČR
Development and application of bioorthogonal reactions in medicine and beyond
Stella Vukelic
AbbVie
Will be announced
Yosef Yarden
Weizmann Institute of Science, Rehovot, Israel
Overcoming resistance of lung cancer to tyrosine kinase inhibitors
